A Phase 2 interventional study of Gilteritinib and Placebo in Acute Myeloid Leukemia (AML) and Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) / Internal Tandem Duplication (ITD) Mutation, sponsored by Astellas Pharma Global Development, Inc.. Completed at 73 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-26.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.
Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 15th largest by enrollment, is one of 3 that started in 2017, is one of 6 in phase 2, and was the 8th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:
The First Affiliated Hospital of Soochow University · Sites in China
Ages 14–70
Technische Universität Dresden · Sites in Germany
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 14+
French Innovative Leukemia Organisation · Sites in France
Ages 18+
By country, each count listing its studies:
gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 16 · Phase 3 10
First in 2013; this study’s year is marked. 3 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 98 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 97 across the 31 interventional studies. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 31 have an industry lead sponsor. The 10 most frequent:
This study is registered under Astellas Pharma Global Development, Inc., one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
22 studies in Leukemia, Myeloid, Acute by Astellas Pharma Inc: none open now, 1 under way, none of them phase 3. Of 19 finished, 11 (58%) have results posted.
Among the 22 studies in Leukemia, Myeloid, Acute by Astellas Pharma Inc, this one is the 7th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2017, is one of 2 in phase 2, and was the 11th registered.
Astellas Pharma Inc’s Leukemia, Myeloid, Acute studies by the year they started, since 2006.
1 of the studies testing gilteritinib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05024552H. Lee Moffitt Cancer Center and Research InstituteVyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML | 2027-02-15 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Astellas Pharma Inc’s 22 in Leukemia, Myeloid, Acute:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to compare relapse-free survival (RFS) between participants with FMS-like tyrosine kinase 3 (FLT3) / internal tandem duplication (ITD) acute myeloid leukemia (AML) in first complete remission (CR1) and who were randomized to receive gilteritinib or placebo beginning after completion of induction/consolidation chemotherapy for a two-year period.
Participants in CR1 were approached for this study after induction/consolidation therapy was complete and a decision not to proceed with transplantation was made or a suitable donor could not be identified. Participants were randomized in a 2:1 ratio to receive gilteritinib or placebo. Participants entered the screening period up to 14 days prior to the start of treatment. Participants were administered treatment over continuous 28-day cycles. Gilteritinib or placebo was given daily for up to 2 years. After treatment discontinuation, participants had a 30-day follow-up visit for safety, after which the participants entered the long-term follow up period for collection of subsequent AML treatment, remission status, and survival (cause of death and date of death). Final database lock will occur when last subject last follow-up visit is reached, per protocol. Study drug was not provided during the follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must meet the following criteria as indicated on the clinical laboratory tests:
Female subject must either:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received gilteritinib 120 mg (three tablets of 40 mg) orally, once daily (QD) for up to 2 years or until a protocol-specified discontinuation criterion was met.
Drug: Gilteritinib
Participants received gilteritinib matching placebo orally, QD for up to 2 years or until a protocol-specified discontinuation criterion was met.
Drug: Placebo
Oral tablet
Also known as: ASP2215
Oral tablet
Relapse-free Survival (RFS) Per Independent Review Committee (IRC) Adjudication
RFS was defined as the time from the date of randomization until the date of documented relapse or death from any cause, whichever occurred first. Relapse after complete remission (CR) \[including complete remission with incomplete platelet recovery (CRp) and Complete remission with incomplete hematologic recovery (CRi)\], was defined as bone marrow blasts 5% or higher (not attributable to regenerating bone marrow), any circulating blasts, any extra-medullary blast foci as per Revised International Working Group (IWG) criteria. Participants were classified as: CRi, if they fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 × 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence was not required. CRp, if they achieved CR except for incomplete platelet recovery (\< 100 × 10\^9/L). RFS was estimated using Kaplan-Meier estimates. hazard ratio (HR), cox proportional hazards model (CHM)
Time frame: From the date of randomization until the date of documented relapse, or death; (Median time on study drug was 427 days for gilteritinib group and 212 days for placebo group)
Overall Survival (OS)
OS was defined as the time from the date of randomization until the date of death from any cause. OS was estimated using Kaplan-Meiers method.
Time frame: From the date of randomization until the date of death from any cause; (Median time on study drug was 427 days for gilteritinib group and 212 days for placebo group)
Event-Free Survival (EFS)
EFS was defined as the time from the date of randomization until the date of documented relapse or discontinuation of the treatment, or initiation of other anti-leukemic treatment or death from any cause, whichever occurred first. Relapse after CR (including CRp and CRi), was defined as bone marrow blasts 5% or higher (not attributable to regenerating bone marrow), any circulating blasts, any extra-medullary blast foci as per Revised IWG criteria. Participants were classified as: CRi, if they fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 × 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence was not required. CRp, if they achieved CR except for incomplete platelet recovery (\< 100 × 10\^9/L). EFS was estimated using Kaplan-Meier's method.
Time frame: From date of randomization until the date of documented relapse or discontinuation of the treatment, or initiation of other anti-leukemic treatment or death from any cause; (Median time on study drug was 427 days for gilteritinib and 212 days for Placebo)
Change From Baseline in Quantitative Minimal Residual Disease Measured as Log10-transformed Overall FLT3/ITD Mutation Ratio at Months 3, 6, 12, 24/End of Treatment (EoT)
MRD was measured from bone marrow samples. FLT3/ITD mutation ratio was measured in relation to total FLT3. For a participant with multiple ITD mutations, the overall FLT3/ITD mutation ratio was calculated from the sum of all ITD mutations. Absence of Minimal Residual Disease (MRD) is defined as log10-transformed overall FLT3/ITD mutation ratio ≤ -4.
Time frame: Baseline and months 3, 6, 12, 24/EoT
Number of Participants With Adverse Events (AE)
An AE is any untoward medical occurrence in a participant administered a study drug, which does not necessarily have to have a causal relationship with treatment. It can, be any unfavorable and unintended sign, symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product whether considered related to the medicinal product. An AE is considered "serious" if, it results in results in death, is life-threatening (an AE is considered "life-threatening" if, its occurrence places the participant at immediate risk of death, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, Requires inpatient hospitalization (except for planned procedures as allowed per study) or leads to prolongation of hospitalization. TEAE was defined as an AE observed after starting administration of the study drug through 30 days after the last dose.
Time frame: From first dose date up to 30 days after last dose or data cut-off date 25-May 2021 (Maximum treatment duration was 744 days)
Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Score
ECOG performance status was measured on an 6 point scale. 0-Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead. Number of participants with ECOG PS was reported. ECOG PS grades with zero participants were not reported.
Time frame: Months 1, 2, 3, 4, 5, 6, 8, 10. 12, 14, 16, 18, 20, 22 and 24/EoT
Adult participants diagnosed with FMS-like tyrosine kinase 3 (FLT3)/internal tandem duplication (ITD) acute myeloid leukemia (AML) in first complete remission (CR1), including complete remission with incomplete platelet recovery (CRp) and complete remission with incomplete hematologic recovery (CRi) for whom a decision not to proceed with transplantation was made, or a suitable donor could not be identified, were enrolled in this study.
| Milestone | Gilteritinib | Placebo |
|---|---|---|
| Started | 63 | 35 |
| Completed | 24 | 12 |
| Not completed | 39 | 23 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Treatment ended due to transplant procedure | 1 | 0 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Becomes eligible for and proceeds to transplant | 0 | 1 |
| Withdrew: Participant relapsed and became eligible for and proceeded to transplant | 0 | 1 |
| Withdrew: Randomized in error | 1 | 0 |
| Withdrew: Participant was not eligible for the study | 1 | 0 |
| Withdrew: Mrd positive | 0 | 1 |
| Withdrew: Disease relapse | 23 | 18 |
| Withdrew: Adverse event | 7 | 1 |
| Withdrew: Investigators decision to take participant off trial due to molecular relapse | 1 | 0 |
| Withdrew: Clinicians decision as suspected relapse | 0 | 1 |
| Milestone | Gilteritinib | Placebo |
|---|---|---|
| Started | 60 | 35 |
| Did not enter long term follow up period | 3 | 0 |
| Completed | 35 | 21 |
| Not completed | 25 | 14 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Death | 23 | 12 |
RFS was defined as the time from the date of randomization until the date of documented relapse or death from any cause, whichever occurred first. Relapse after complete remission (CR) \[including complete remission with incomplete platelet recovery (CRp) and Complete remission with incomplete hematologic recovery (CRi)\], was defined as bone marrow blasts 5% or higher (not attributable to regenerating bone marrow), any circulating blasts, any extra-medullary blast foci as per Revised International Working Group (IWG) criteria. Participants were classified as: CRi, if they fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 × 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence was not required. CRp, if they achieved CR except for incomplete platelet recovery (\< 100 × 10\^9/L). RFS was estimated using Kaplan-Meier estimates. hazard ratio (HR), cox proportional hazards model (CHM)
| Months | Gilteritinib | Placebo |
|---|---|---|
| Relapse-free Survival (RFS) Per Independent Review Committee (IRC) Adjudication | 24.02 (14.06 to NA) | 15.84 (3.02 to NA) |
OS was defined as the time from the date of randomization until the date of death from any cause. OS was estimated using Kaplan-Meiers method.
| Months | Gilteritinib | Placebo |
|---|---|---|
| Overall Survival (OS) | NA (30.42 to NA) | NA (43.56 to NA) |
EFS was defined as the time from the date of randomization until the date of documented relapse or discontinuation of the treatment, or initiation of other anti-leukemic treatment or death from any cause, whichever occurred first. Relapse after CR (including CRp and CRi), was defined as bone marrow blasts 5% or higher (not attributable to regenerating bone marrow), any circulating blasts, any extra-medullary blast foci as per Revised IWG criteria. Participants were classified as: CRi, if they fulfilled all the criteria for CR except for incomplete hematological recovery with residual neutropenia \< 1 × 10\^9/L with or without complete platelet recovery. RBC and platelet transfusion independence was not required. CRp, if they achieved CR except for incomplete platelet recovery (\< 100 × 10\^9/L). EFS was estimated using Kaplan-Meier's method.
| Months | Gilteritinib | Placebo |
|---|---|---|
| Event-Free Survival (EFS) | 14.06 (9.89 to 23.72) | 6.74 (2.86 to 21.95) |
MRD was measured from bone marrow samples. FLT3/ITD mutation ratio was measured in relation to total FLT3. For a participant with multiple ITD mutations, the overall FLT3/ITD mutation ratio was calculated from the sum of all ITD mutations. Absence of Minimal Residual Disease (MRD) is defined as log10-transformed overall FLT3/ITD mutation ratio ≤ -4.
| Ratio | Gilteritinib | Placebo |
|---|---|---|
| Month 3 | 0.14 ± 0.96 | 0.14 ± 1.46 |
| Month 6 | 0.07 ± 0.92 | -0.17 ± 0.79 |
| Month 12 | -0.11 ± 0.60 | -0.34 ± 0.67 |
| Month 24/EoT | -0.12 ± 1.08 | 0.23 ± 1.63 |
An AE is any untoward medical occurrence in a participant administered a study drug, which does not necessarily have to have a causal relationship with treatment. It can, be any unfavorable and unintended sign, symptom or disease (new or exacerbated) temporally associated with the use of a medicinal product whether considered related to the medicinal product. An AE is considered "serious" if, it results in results in death, is life-threatening (an AE is considered "life-threatening" if, its occurrence places the participant at immediate risk of death, results in persistent or significant disability/incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly or birth defect, Requires inpatient hospitalization (except for planned procedures as allowed per study) or leads to prolongation of hospitalization. TEAE was defined as an AE observed after starting administration of the study drug through 30 days after the last dose.
| Participants | Gilteritinib | Placebo |
|---|---|---|
| TEAE | 58 | 33 |
| Drug-Related TEAE | 51 | 20 |
| TEAE before Relapse | 57 | 28 |
| Drug-Related TEAE before Relapse | 51 | 15 |
| Serious TEAE | 24 | 14 |
| Drug-Related Serious TEAE | 10 | 3 |
| TEAE Leading to Death | 1 | 1 |
| Drug-Related TEAE Leading to Death | 0 | 1 |
| TEAE Leading to Withdrawal of Treatment | 15 | 6 |
| Drug-Related TEAE Leading to Withdrawal of Treatment | 5 | 2 |
| TEAE Leading to Dose Reduction | 15 | 1 |
| Drug-Related TEAE Leading to Dose Reduction | 14 | 1 |
| TEAE Leading to Dose Interruption | 35 | 4 |
| Drug-Related TEAE Leading to Dose Interruption | 31 | 1 |
| Grade 3 or Higher Treatment-Emergent Adverse Events | 42 | 18 |
| Grade 3 or Higher Drug-related TEAE | 33 | 4 |
| Death | 20 | 11 |
ECOG performance status was measured on an 6 point scale. 0-Fully active, able to carry on all pre-disease performance without restriction. 1. Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work. 2. Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours. 3. Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. 4. Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair. 5. Dead. Number of participants with ECOG PS was reported. ECOG PS grades with zero participants were not reported.
| Participants | Gilteritinib | Placebo |
|---|---|---|
| Baseline: Grade 0 | 39 | 22 |
| Baseline: Grade 1 | 23 | 13 |
| Month 2: Grade 0 | 38 | 18 |
| Month 2: Grade 1 | 16 | 9 |
| Month 2: Grade 2 | 0 | 1 |
| Month 3: Grade 0 | 33 | 20 |
| Month 3: Grade 1 | 19 | 4 |
| Month 3: Grade 2 | 0 | 1 |
| Month 4: Grade 0 | 37 | 16 |
| Month 4: Grade 1 | 12 | 6 |
| Month 5: Grade 0 | 35 | 17 |
| Month 5: Grade 1 | 11 | 4 |
| Month 6: Grade 0 | 32 | 17 |
| Month 6: Grade 1 | 11 | 2 |
| Month 8: Grade 0 | 32 | 12 |
| Month 8: Grade 1 | 8 | 6 |
| Month 8: Grade 2 | 1 | 0 |
| Month 10: Grade 0 | 29 | 14 |
| Month 10: Grade 1 | 8 | 3 |
| Month 12: Grade 0 | 24 | 14 |
| Month 12: Grade 1 | 11 | 3 |
| Month 14: Grade 0 | 21 | 13 |
| Month 14: Grade 1 | 9 | 3 |
| Month 16: Grade 0 | 22 | 11 |
| Month 16: Grade 1 | 4 | 2 |
| Month 16: Grade 2 | 2 | 0 |
| Month 18: Grade 0 | 19 | 13 |
| Month 18: Grade 1 | 8 | 1 |
| Month 20: Grade 0 | 18 | 13 |
| Month 20: Grade 1 | 7 | 1 |
| Month 22: Grade 0 | 20 | 11 |
| Month 22: Grade 1 | 4 | 2 |
| Month 24/EoT: Grade 0 | 34 | 20 |
| Month 24/EoT: Grade 1 | 14 | 6 |
| Month 24/EoT: Grade 2 | 1 | 0 |
| Month 24/EoT: Grade 3 | 1 | 1 |
| Month 24/EoT: Grade 4 | 1 | 1 |
Collected over From the date of randomization up to end of study (85 months and 9 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Gilteritinib | 24/63 (38.1%) | 24/62 (38.7%) | 53/62 (85.5%) |
| Placebo | 12/35 (34.3%) | 14/35 (40%) | 32/35 (91.4%) |
| Event | Gilteritinib | Placebo |
|---|---|---|
| Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 7/62 | 5/35 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/62 | 1/35 |
| HyperleukocytosisBlood and lymphatic system disorders | 0/62 | 1/35 |
| NeutropeniaBlood and lymphatic system disorders | 1/62 | 1/35 |
| Anal haemorrhageGastrointestinal disorders | 0/62 | 1/35 |
| NauseaGastrointestinal disorders | 0/62 | 1/35 |
| VomitingGastrointestinal disorders | 0/62 | 1/35 |
| PyrexiaGeneral disorders | 0/62 | 1/35 |
| InfluenzaInfections and infestations | 0/62 | 1/35 |
| Back painMusculoskeletal and connective tissue disorders | 0/62 | 1/35 |
| Event | Gilteritinib | Placebo |
|---|---|---|
| Blood creatine phosphokinase increasedInvestigations | 18/62 | 1/35 |
| NauseaGastrointestinal disorders | 8/62 | 7/35 |
| Neutrophil count decreasedInvestigations | 12/62 | 3/35 |
| Platelet count decreasedInvestigations | 12/62 | 4/35 |
| ThrombocytopeniaBlood and lymphatic system disorders | 11/62 | 4/35 |
| NasopharyngitisInfections and infestations | 7/62 | 6/35 |
| NeutropeniaBlood and lymphatic system disorders | 10/62 | 1/35 |
| FatigueGeneral disorders | 10/62 | 3/35 |
| CoughRespiratory, thoracic and mediastinal disorders | 9/62 | 2/35 |
| AnaemiaBlood and lymphatic system disorders | 5/62 | 5/35 |
The full analysis set (FAS) consisted of all participants who were randomized.
| Age, Continuous(Years) | Gilteritinib | Placebo | Total |
|---|---|---|---|
| Mean | 61.4 ± 11.0 | 59.9 ± 13.9 | 60.9 ± 12.1 |
| Sex: Female, Male(Participants) | Gilteritinib | Placebo | Total |
|---|---|---|---|
| Female | 31 | 20 | 51 |
| Male | 32 | 15 | 47 |
| Ethnicity (NIH/OMB)(Participants) | Gilteritinib | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 3 | 9 |
| Not Hispanic or Latino | 50 | 29 | 79 |
| Unknown or Not Reported | 7 | 3 | 10 |
| Race (NIH/OMB)(Participants) | Gilteritinib | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 17 | 10 | 27 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 38 | 22 | 60 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 8 | 3 | 11 |
| Age (<60 or ≥60 years)(Participants) | Gilteritinib | Placebo | Total |
|---|---|---|---|
| <60 years | 24 | 13 | 37 |
| ≥60 years | 39 | 22 | 61 |
| Geographic Region(Participants) | Gilteritinib | Placebo | Total |
|---|---|---|---|
| North America | 5 | 4 | 9 |
| Europe | 40 | 20 | 60 |
| Rest of the world | 18 | 11 | 29 |
| Presence of MRD(Participants) | Gilteritinib | Placebo | Total |
|---|---|---|---|
| MRD = Yes | 8 | 6 | 14 |
| MRD = No | 55 | 29 | 84 |
| Use of FLT3-inhibitors(Participants) | Gilteritinib | Placebo | Total |
|---|---|---|---|
| Use of FLT3 Inhibitor = Yes | 12 | 10 | 22 |
| Use of FLT3 Inhibitor = No | 51 | 25 | 76 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
Ran from Jan 2017 to primary completion in May 2021, 52 months.
Results were first posted in Jun 2022, 1 year 1 month after primary completion.
Of 57 industry-sponsored phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 55. This study's 52 months is above that.
Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gilteritinib
Astellas Pharma Global Development, Inc. →